Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Overweight on Anthem, Raises Price Target to $607

Morgan Stanley analyst Ricky Goldwasser maintains Anthem (NYSE:ANTM) with a Overweight and raises the price target from $518 to $607.

byBenzinga Newsdesk

April 21, 2022

1 minute read

Morgan Stanley analyst Ricky Goldwasser maintains Anthem (NYSE:ANTM) with a Overweight and raises the price target from $518 to $607.

Goldman Sachs Maintains Buy on Vertiv Holdings, Lowers Price Target to $16

By Benzinga Newsdesk

Today, 11:48 AM

Goldman Sachs maintains Vertiv Holdings (NYSE:VRT) with a Buy and lowers the price target from $18 to $16.

VRT

ProMIS Neurosciences Q3 EPS $(0.85) Down From $(0.20) YoY

By Benzinga Newsdesk

Today, 11:48 AM

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.85) per share. This is a 325 percent decrease over losses of $(0.20) per share from the same period last year.

PMN

News

White House’s John Kirby Says Putin Still Has A Lot Of Military Capacity Left At His Disposal, Not Just To Be Used In Ukraine

By Benzinga Newsdesk

Today, 11:48 AM

- Reuters

RSX

SCYNEXIS Announces Submission Of Supplemental New Drug Application Of BREXAFEMME To FDA For An Expanded Indication For Prevention Of Recurrent Vaginal Yeast Infections

By Bill Haddad

Today, 11:48 AM

Regulatory submission for the label extension is supported by positive data from the pivotal Phase 3 CANDLE study in which ibrexafungerp successfully achieved statistically significant superiority over placebo

SCYX

Morgan Stanley Maintains Overweight on Anthem, Raises Price Target to $607

Related Posts

Goldman Sachs Maintains Buy on Vertiv Holdings, Lowers Price Target to $16

ProMIS Neurosciences Q3 EPS $(0.85) Down From $(0.20) YoY

White House’s John Kirby Says Putin Still Has A Lot Of Military Capacity Left At His Disposal, Not Just To Be Used In Ukraine

SCYNEXIS Announces Submission Of Supplemental New Drug Application Of BREXAFEMME To FDA For An Expanded Indication For Prevention Of Recurrent Vaginal Yeast Infections